Holen Sie sich die Stockscreener-App
34.67
6.15%
2.01
Vorhandelsmarkt:
35.89
1.22
+3.52%
Schlusskurs vom Vortag:
$32.66
Offen:
$33.41
24-Stunden-Volumen:
1.98M
Relative Volume:
1.32
Marktkapitalisierung:
$6.36B
Einnahmen:
$520.18M
Nettoeinkommen (Verlust:
$-348.13M
KGV:
-18.06
EPS:
-1.92
Netto-Cashflow:
$-176.18M
1W Leistung:
+9.58%
1M Leistung:
+1.73%
6M Leistung:
-40.98%
1J Leistung:
-38.83%
1-Tages-Spanne:
$33.19
$35.93
1-Wochen-Bereich:
$31.18
$35.93
52-Wochen-Spanne:
$30.17
$70.13
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Firmenname
Legend Biotech Corp Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie LEGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
34.67 | 6.36B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-06-17 | Eingeleitet | Truist | Buy |
| 2024-05-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Buy |
| 2024-04-17 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | Raymond James | Outperform |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-11-06 | Eingeleitet | Goldman | Buy |
| 2023-05-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-05-22 | Eingeleitet | Daiwa Securities | Buy |
| 2023-03-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-11-02 | Eingeleitet | Evercore ISI | Outperform |
| 2022-11-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-03-15 | Eingeleitet | Barclays | Overweight |
| 2022-01-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-07-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Legend Biotech Corp Adr Aktie (LEGN) Neueste Nachrichten
Legend Biotech keeps stock at Buy rating on strong position - Investing.com India
When will lagging health care stocks return to healthy growth? - The Globe and Mail
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential - Investing.com India
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential By Investing.com - Investing.com South Africa
Legend Biotech's SWOT analysis: carvykti sales boost stock amid competition - Investing.com India
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook By Investing.com - Investing.com South Africa
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook - Investing.com India
Overweight rating for Legend Biotech reflects confidence in long-term CARVYKTI revenue - Investing.com India
Legend Biotech stock hits 52-week low at $32.65 amid market challenges - Investing.com
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid challenges - Investing.com India
Legend Biotech stock hits 52-week low at $36.9 amid market shifts By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $36.9 amid market shifts - Investing.com
Analysts Expect ACWI To Hit $136 - Nasdaq
Earnings call: Legend Biotech sees strong growth with CARVICTI sales - Investing.com India
Earnings call: Legend Biotech sees robust growth with CARVICTI sales - Investing.com
Legend Biotech Corp ADR (NASDAQ: LEGN) Has Great Upside Potential - Stocks Register
Thinking Of Investing In Bilibili Inc ADR (NASDAQ: BILI) Stock? Read This First - Stocks Register
Are Medtronic Plc (NYSE: MDT) Analysts Predicting A Spike? - Stocks Register
Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Parkway Corporate Limited Announces New Securities Issuance - MSN
Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com
Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa
Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com
Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Legend Biotech appoints new President for CARVYKTI - Investing.com
Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance
Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register
Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India
Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India
Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily
Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily
Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily
BMO maintains steady target on Legend Biotech on strong sales - Investing.com
BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa
Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex
Legend Biotech Corp ADR’s results are impressive - US Post News
Finanzdaten der Legend Biotech Corp Adr-Aktie (LEGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):